PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13133793::ACT044557

LCKLSL

Evidence text

Paper-level observation

10 μM LCKLSL treatment significantly suppressed surface tPA binding in HRMECs under stimulation of hypoxia (1% O2) and VEGF (20 ng/ml) (Figure 9B)
textConfidence: medium

Assay observation

Activity
Other
Subtype
Protein binding inhibition
Measure
percent_inhibition
Comparator
=
Raw observation
significantly suppressed surface tPA binding
Normalized measurement
=10
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
HRMEC
Assay method
Not reported by source
Sequence
LCKLSL
Standardization
ready simple

Source publication

Study on the Role of Short Peptide LCKLSL Targeting ANXA2 in Retinal Neovascularization.

In Vivo · 2026

DOI 10.21873/invivo.14291 PMC13133793
Parent mention

Related peptide identities

PEPDIA-PLP-001707

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.